Chenyu Xu1, Richard Y Wang, Cathy A Schechterly, Shengxiang Ge, James W Shih, Ning-Shao Xia, Naomi L C Luban, Harvey J Alter. 1. Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland; National Institute of Diagnostics and Vaccine Development in Infectious Disease, School of Public Health, Xiamen University, Xiamen, Fujian, China; Department of Laboratory Medicine, Center for Cancer and Blood Diseases, Children's National Medical Center; Department of Pediatrics, School of Medicine and Health Sciences, George Washington University, Washington, DC.
Abstract
BACKGROUND: Hepatitis E virus (HEV) infection has become relevant to blood transfusion practice because isolated cases of blood transmission have been reported and because HEV has been found to cause chronic infection and severe liver disease in immunocompromised patients. STUDY DESIGN AND METHODS: We tested for immunoglobulin (Ig)G and IgM antibodies to the HEV and for HEV RNA in 1939 unselected volunteer US blood donors. Subsequently, we tested the same variables in pre- and serial posttransfusion samples from 362 prospectively followed blood recipients to assess transfusion risk. RESULTS: IgG anti-HEV seroprevalence in the total 1939 donations was 18.8%: 916 of these donations were made in 2006 at which time the seroprevalence was 21.8% and the remaining 1023 donations were in 2012 when the seroprevalence had decreased to 16.0% (p < 0.01). A significant (p < 0.001) stepwise increase in anti-HEV seroprevalence was seen with increasing age. Eight of 1939 donations (0.4%) tested anti-HEV IgM positive; no donation was HEV RNA positive. Two recipients had an apparent anti-HEV seroconversion, but temporal relationships and linked donor testing showed that these were not transfusion-transmitted HEV infections. CONCLUSION: No transfusion-transmitted HEV infections were observed in 362 prospectively followed blood recipients despite an anti-HEV seroprevalence among donations exceeding 16%. Published 2013. This article is a U.S. Government work and is in the public domain in the USA.
BACKGROUND:Hepatitis E virus (HEV) infection has become relevant to blood transfusion practice because isolated cases of blood transmission have been reported and because HEV has been found to cause chronic infection and severe liver disease in immunocompromised patients. STUDY DESIGN AND METHODS: We tested for immunoglobulin (Ig)G and IgM antibodies to the HEV and for HEV RNA in 1939 unselected volunteer US blood donors. Subsequently, we tested the same variables in pre- and serial posttransfusion samples from 362 prospectively followed blood recipients to assess transfusion risk. RESULTS: IgG anti-HEV seroprevalence in the total 1939 donations was 18.8%: 916 of these donations were made in 2006 at which time the seroprevalence was 21.8% and the remaining 1023 donations were in 2012 when the seroprevalence had decreased to 16.0% (p < 0.01). A significant (p < 0.001) stepwise increase in anti-HEV seroprevalence was seen with increasing age. Eight of 1939 donations (0.4%) tested anti-HEV IgM positive; no donation was HEV RNA positive. Two recipients had an apparent anti-HEV seroconversion, but temporal relationships and linked donor testing showed that these were not transfusion-transmitted HEV infections. CONCLUSION: No transfusion-transmitted HEV infections were observed in 362 prospectively followed blood recipients despite an anti-HEV seroprevalence among donations exceeding 16%. Published 2013. This article is a U.S. Government work and is in the public domain in the USA.
Authors: Harry R Dalton; Nassim Kamar; Jeroen J J van Eijk; Brendan N Mclean; Pascal Cintas; Richard P Bendall; Bart C Jacobs Journal: Nat Rev Neurol Date: 2015-12-29 Impact factor: 42.937
Authors: Mohammad Zafrullah; Xiugen Zhang; Coleen Tran; Megan Nguyen; Saleem Kamili; Michael A Purdy; Susan L Stramer Journal: Transfusion Date: 2018-03-09 Impact factor: 3.157
Authors: John R Ticehurst; Nora Pisanic; Michael S Forman; Carly Ordak; Christopher D Heaney; Edgar Ong; Jeffrey M Linnen; Paul M Ness; Nan Guo; Hua Shan; Kenrad E Nelson Journal: Transfusion Date: 2019-01-31 Impact factor: 3.157
Authors: David R McGivern; Hsing-Hua S Lin; Junyao Wang; Tiffany Benzine; Harry L A Janssen; Mandana Khalili; Mauricio Lisker-Melman; Robert J Fontana; Steven H Belle; Michael W Fried Journal: Open Forum Infect Dis Date: 2019-04-09 Impact factor: 3.835